WuXi Biologics Begins Construction of 1.3-Million-Sq-Ft-Mfg Center in China

By Patricia Van Arnum - DCAT Editorial Director

May 16, 2019

WuXi Biologics, a contract biologics manufacturer, has begun construction of 1.3-million square foot manufacturing center in Chengdu, China, in southwest China.

The new integrated manufacturing center will include drug development and commercial manufacturing facilities with initial bioreactor capacity of 48,000 liters. The facility will house the twelfth drug-substances manufacturing facility of WuXi Biologics.

As of December 31, 2018, WuXi Biologics had a total of 205 integrated projects, including 97 projects in preclinical development stage, 94 projects in early-phase (Phase I and II) clinical development, 13 projects in late-phase (Phase III) development, and one project in commercial manufacturing. The company has total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2022.

Source: WuXi Biologics